New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2014
08:16 EDTECYTEndocyte announces Phase 2b TARGET Phase 2b study met primary endpoint
Endocyte announced results from the Phase 2b TARGET trial, which showed that the study met the primary endpoint for the combination of vintafolide and docetaxel in folate receptor, or FR,-positive recurrent non-small cell lung cancer, or NSCLC, patients. As a randomized Phase 2b study, the pre-defined statistical threshold for significance was a p-value of < 0.10. The data showed that risk of disease worsening or death was reduced by 25% for patients treated with the vintafolide/docetaxel combination versus docetaxel alone. Detailed trial results, including data regarding overall survival, or OS, will be presented at an upcoming medical conference. The TARGET Phase 2b trial was conducted in 199 patients, randomized to one of three arms: vintafolide alone, vintafolide/docetaxel combination, or docetaxel alone. Secondary endpoints, including overall response rate and OS, also showed trends in favor of the combination arm. Median OS has been reached for the vintafolide and docetaxel single-agent arms but has not yet been reached in the combination arm. In addition, the investigational combination regimen showed better activity in patients with adenocarcinoma, a subset analysis pre-specified in the trial design. The safety profile of the combination arm was consistent with those observed with docetaxel alone and vintafolide alone, though a higher rate of hematologic and peripheral neuropathy adverse events were observed in the combination arm. There were no drug-related deaths in the combination arm. Single-agent vintafolide at the schedule evaluated in this study demonstrated less activity than single-agent docetaxel.
News For ECYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ECYT

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use